Author

Xiwu Hui

Observed institution: CSPC Pharmaceutical Group

ORCID: 0009-0001-8913-2194

Observed ORCID: 0009-0001-8913-2194

OpenAlex ID: A5147911099

Table S12 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors

2026 · Zhaopeng Sun, Mo Dan, et al.

Data from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors

2026 · Zhaopeng Sun, Mo Dan, et al.

Figure S4 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors

2026 · Zhaopeng Sun, Mo Dan, et al.

Figure S10 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors

2026 · Zhaopeng Sun, Mo Dan, et al.

Table S8 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors

2026 · Zhaopeng Sun, Mo Dan, et al.

Table S13 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors

2026 · Zhaopeng Sun, Mo Dan, et al.

Table S9 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors

2026 · Zhaopeng Sun, Mo Dan, et al.

Figure 2 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors

2026 · Zhaopeng Sun, Mo Dan, et al.

Table 1 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors

2026 · Zhaopeng Sun, Mo Dan, et al.

Figure S3 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors

2026 · Zhaopeng Sun, Mo Dan, et al.

Table S2 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors

2026 · Zhaopeng Sun, Mo Dan, et al.

Table S10 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors

2026 · Zhaopeng Sun, Mo Dan, et al.

Figure 4 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors

2026 · Zhaopeng Sun, Mo Dan, et al.

Supplementary Methods from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors

2026 · Zhaopeng Sun, Mo Dan, et al.

Figure S8 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors

2026 · Zhaopeng Sun, Mo Dan, et al.

Figure S7 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors

2026 · Zhaopeng Sun, Mo Dan, et al.

Figure 5 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors

2026 · Zhaopeng Sun, Mo Dan, et al.

Figure S5 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors

2026 · Zhaopeng Sun, Mo Dan, et al.

Table S1 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors

2026 · Zhaopeng Sun, Mo Dan, et al.

Figure S6 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors

2026 · Zhaopeng Sun, Mo Dan, et al.

Figure S1 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors

2026 · Zhaopeng Sun, Mo Dan, et al.

Figure 3 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors

2026 · Zhaopeng Sun, Mo Dan, et al.

Table S6 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors

2026 · Zhaopeng Sun, Mo Dan, et al.

Figure S9 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors

2026 · Zhaopeng Sun, Mo Dan, et al.

Figure 1 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors

2026 · Zhaopeng Sun, Mo Dan, et al.

Works count: 32

Citation count:

H-index:

I10-index: